



Excessive and Inappropriate Inflammatory Process **Associated to a Dysfunction of Intestinal Barrier: Loss of Mucosal Immune Homeostasis** Minor Zonulin-dependent Massive dietary and Normal/physiologically Increased barrier defect dietary/ controlled permeability permeability microbial antigen influx microbial Ag influx Defensing Mucus ynthesis & Quality Inflammation - Allergy **Mucosal Tolerance Break of Tolerance Homeostasis** Anergy Non-infective low grade **Vicious** inflammation: circle 1. Visceral hypersensitivity (IBS); Regulatory DC's Innate or immuno-2. Th1 immune response (chronic Macrophages ...Tight junctions are a 'dark horse' implicated inflammation); Tregs IL-10/TGF-β in a host of disease states, ranging from acute 3. Th2 immune response (food Proinflammatory injury to chronic inflammation and allergies); 4. Th17 immune response Allergic cytokines autoimmune diseases (autoimmunity). Adapted from P. Brandtzaeg, Beneficial Microbes 2010


Alessio Fasano, MD

5

6








Ztm Showed Increased Morbidity (Colonic Mucosal Damage) And Mortality (70%) Following DSS-Induced Colitis **DSS-induced Mortality in Ztm Mice** Zonulin Transgenic 3% DSS Male Percent survival 60 40 C57Bl/6 Untreated Zonulin transgenic Hp2 Untreated C57Bl/6 DSS ulin transgenic Hp2 DSS 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 in vivo - FITC-dextran Zonulin Inhibitor Larazotide Rescued Ztm Ε 100 Zonulin transgenic Percent survival 80 60 Sturgeon C et al. Ann NY Acad Sci 2017 6 7 8 9 10 11 12 13 14


Alessio Fasano, MD 5


Day







12






14







то





The Wisdom of Microscopic Species

| Infant | In











22








Fixed spelling of independent Owner, 7/13/2012 2


Added abbreviation LGG for Lactobacillus GG since he uses it later. 1

Owner, 7/13/2012













28







30















-




Microbiome signatures of progression toward celiac disease onset in at-risk children in a longitudinal prospective cohort study Maureen M. Leonard^{a,b,c}, Francesco Valitutti^{d,e,1}, Hiren Karathia^{f,1}, Meritxell Pujolassos^{g,1}, Victoria Kenyon^{b,c,1}, Brian Fanelli^{f,1}, Jacopo Troisi^{d,g,h}, Poorani Subramanian^{f,1}, Stephanie Camhi^{b,c}, Angelo Colucci^{g,h}, Gloria Serena Ab,c, Salvatore Cucchiara 0, Chiara Maria Trovato 0, Basilio Malamisura , Ruggiero Francavilla , Luca Elli 0, Nur A. Hasan , Ali R. Zomorrodi^{a,b,c}, Rita Colwell^{f,m,2}, Alessio Fasano^{a,b,c,d,2}, and The CD-GEMM Team³ Significance **Longitudinal Analysis Cross-Sectional Analysis** The incidence of chronic inflammatory autoimmune conditions such as celiac disease (CD), is increasing at an alarming rate. CD is the only autoimmune condition for which the trigger, gluten, is known. However, its etiology and pathogenesis remain incompletely defined as recent studies suggest other environmental stimuli may play a key role in CD pathogenesis. Here, we prospectively examine the trajectory of the gut microbiota starting 18 mo before CD onset in 10 infants who developed CD and 10 infants who did not. We identified alterations in the gut and to little who can be to the tolerance alterations in the gut microbiota, functional pathways, and metabolome before CD onset, suggesting our approach may be used for disease predic-tion with the ultimate goal of identifying early preventive interventions to reestablish tolerance and prevent autoimmunity. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29)::e2020322118

Alessio Fasano, MD


38

Longitudinal analysis provided more in-depth data by William identifying microbes, pathways and metabolites with differential abundance CD onset

Cases



· Previously linked to autoimmune and inflammatory conditions



- Previously reported as probiotics or having anti-inflammatory properties
- Previously unreported microbes/pathways/metabolites that may serve as CD-specific biomarkers

Controls


A

Abundance of microbes/pathways/metabolites


 Previously linked to protection against allergic, autoimmune and inflammatory conditions Laparra JM, Plosone, 2012. Wong CB et al. Nutrients 2019 Klemenak M et al. Dig Dis Sci 2015 Stewart, Nature, 2018. Ye, Microbiome 2018.

Pianta, J Clin Invest, 2017 Menard S et al, Gut, 2004. Chien Mw et al, Int j of Mol sci, 2018

39



40



Manipulating The Microbiome To Treat CID



Microbiome Disruption by Condition Summary





CONDITION	RELEVANT FINDINGS				
Prematurity	† Proteobacteria				
	↓ Microbial diversity				
Necrotizing enterocolitis	Blooms of Proteobacteria prior to disease onset				
Sepsis	Altered microbiota structure and composition prior to disease onset has been reported, but specific microbiota reported is inconsistent acro				
	studies				
Colic	Decreased microbial diversity and increased anaerobic bacteria				
Malnutrition	Anaerobic depletion, early dysbiosis, and intestinal pathogenic overabundance with decreased bacterial diversity				
Eczema	Early colonization with opportunistic species may be important in disease initiation				
Allergies	↓ Species diversity				
Asthma	No clear pattern				
Inflammatory bowel	Data is sparse, no consistent pattern				
disease					
Type I diabetes	↑ Bacteroidetes: Firmicutes ratios,				
	↑ Clostridia species				
	↓ Butyrate-producing bacteria				
	↓ Bacterial diversity				
	↓ Community stability				
	Alterations in the microbiome seem to precede disease onset				
Type II diabetes and	† Firmicutes: Bacteroidetes ratio				
obesity	↑ SCFAs				
Autism spectrum disorder	↑ Clostridial species				
	↑ Suttetrella and Desulfovibrio species				

43



EVIDENCE FOR USE OF PROBIOTICS IN PEDIATRICS





Condition	Prevention*	Treatment*	Probiotic species	Typical daily dose (CFU/d)
Colic (breastfed)6-8	0	+	Lactobacillus reuteri	100 million
Atopic eczema ¹³⁻¹⁷	+	0	Lactobacillus rhamnosus, Lactobacillus paracasei, Bifidobacterium lactis	3-6 billion
URI ⁹⁻¹²	+	+	Lactobacillus and Bifidobacterium spp	2-10 billion
IBS ¹⁸⁻²⁰	Not studied	+	L rhamnosus VSL#3 [†]	6 billion 450-900 billion
AAD ²¹⁻²⁴	+	+	L rhamnosus, Saccharomyces boulardii	20 billion
AID ²³⁻²⁹	Not studied	+	L rhamnosus, S boulardii, Bifidobacterium bifidum, Bifidobacterium infantis	10 billion

AAD, antibiotic-associated diarrhea; AID, acute infectious diarrhea; CFU/d, colony forming units per day; IBS, irritable bowel syndrome; URI, upper respiratory infection.

associated with most diseases.

44

^{* 0=}no effect; +=positive effect

¹Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, and Streptococcus hermophiles.



PRACTICE RECOMMENDATIONS FOR THE USE OF PROBIOTICS



- > Recommend a trial of Lactobacillus reuteri for breastfed infants with colic. A
- > Consider Lactobacillus and Bifidobacterium species for the prevention of upper respiratory infections (URIs) and to shorten the course of URI illness.
- > Do not recommend probiotics for the prevention of respiratory or gastrointestinal allergies. A
- > Consider probiotics for the reduction of abdominal pain in pediatric irritable bowel syndrome, as well as to reduce diarrhea associated with antibiotic use and acute gastroenteritis. A


Strength of recommendation (SOR)

- A Good-quality patient-oriented evidence
- **B** Inconsistent or limited-quality patient-oriented evidence
- C Consensus, usual practice, opinion, disease-oriented evidence, case series

45



46





48

